tetano
Editor, Senior Moderator
Anal Methods
. 2022 Dec 5.
doi: 10.1039/d2ay01530g. Online ahead of print.
Trimetallic Au@Pd@Pt nanozyme-enhanced lateral flow immunoassay for the detection of SARS-CoV-2 nucleocapsid protein
Yue Sun[SUP] 1 2 [/SUP], Zihao Xie[SUP] 1 2 [/SUP], Fubin Pei[SUP] 1 2 [/SUP], Wei Hu[SUP] 2 [/SUP], Shasha Feng[SUP] 1 2 [/SUP], Qingli Hao[SUP] 1 [/SUP], Bing Liu[SUP] 2 [/SUP], Xihui Mu[SUP] 2 [/SUP], Wu Lei[SUP] 1 [/SUP], Zhaoyang Tong[SUP] 2 [/SUP]
Affiliations
Abstract
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seriously threatened global public health. Establishing a rapid and sensitive diagnostic test for early detection of the SARS-CoV-2 nucleocapsid protein is urgently required to defend against the pandemic. Herein, an enhanced lateral flow immunoassay (LFIA) was fabricated by trimetallic Au@Pd@Pt core-shell nanozymes for detection of the SARS-CoV-2 nucleocapsid protein. The Au@Pd@Pt nanozymes (Au@Pd@Pt NZs) synthesized via a one-pot method, with a dendrite morphology and uniform particle size, showed excellent peroxidase-like activity. Due to the perfect enzyme-like catalytic activity toward 3,3',5,5'-tetramethylbenzidine (TMB) in the presence of hydrogen peroxide (H[SUB]2[/SUB]O[SUB]2[/SUB]), the catalytic signal could be generated even by a tiny amount of Au@Pd@Pt NZs accumulated on the test strip. Therefore, rapid detection with higher sensitivity was achieved. The Au@Pd@Pt NZs-based LFIA provided a quantitative range of 0.05-100 ng mL[SUP]-1[/SUP] with a limit of detection of 0.037 ng mL[SUP]-1[/SUP], which was 17-fold lower than the LFIA without enhancement. The average recoveries from spiked samples were in the range of 92.5-107.9% with relative standard deviations all less than 4%, indicating the reliability and repeatability of the proposed LFIA. Additionally, the proposed LFIA could report results within 30 min using a microplate reader. In conclusion, the Au@Pd@Pt NZs-LFIA is a rapid, simple, and sensitive method for detecting the SARS-CoV-2 nucleocapsid protein.
. 2022 Dec 5.
doi: 10.1039/d2ay01530g. Online ahead of print.
Trimetallic Au@Pd@Pt nanozyme-enhanced lateral flow immunoassay for the detection of SARS-CoV-2 nucleocapsid protein
Yue Sun[SUP] 1 2 [/SUP], Zihao Xie[SUP] 1 2 [/SUP], Fubin Pei[SUP] 1 2 [/SUP], Wei Hu[SUP] 2 [/SUP], Shasha Feng[SUP] 1 2 [/SUP], Qingli Hao[SUP] 1 [/SUP], Bing Liu[SUP] 2 [/SUP], Xihui Mu[SUP] 2 [/SUP], Wu Lei[SUP] 1 [/SUP], Zhaoyang Tong[SUP] 2 [/SUP]
Affiliations
- PMID: 36468531
- DOI: 10.1039/d2ay01530g
Abstract
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seriously threatened global public health. Establishing a rapid and sensitive diagnostic test for early detection of the SARS-CoV-2 nucleocapsid protein is urgently required to defend against the pandemic. Herein, an enhanced lateral flow immunoassay (LFIA) was fabricated by trimetallic Au@Pd@Pt core-shell nanozymes for detection of the SARS-CoV-2 nucleocapsid protein. The Au@Pd@Pt nanozymes (Au@Pd@Pt NZs) synthesized via a one-pot method, with a dendrite morphology and uniform particle size, showed excellent peroxidase-like activity. Due to the perfect enzyme-like catalytic activity toward 3,3',5,5'-tetramethylbenzidine (TMB) in the presence of hydrogen peroxide (H[SUB]2[/SUB]O[SUB]2[/SUB]), the catalytic signal could be generated even by a tiny amount of Au@Pd@Pt NZs accumulated on the test strip. Therefore, rapid detection with higher sensitivity was achieved. The Au@Pd@Pt NZs-based LFIA provided a quantitative range of 0.05-100 ng mL[SUP]-1[/SUP] with a limit of detection of 0.037 ng mL[SUP]-1[/SUP], which was 17-fold lower than the LFIA without enhancement. The average recoveries from spiked samples were in the range of 92.5-107.9% with relative standard deviations all less than 4%, indicating the reliability and repeatability of the proposed LFIA. Additionally, the proposed LFIA could report results within 30 min using a microplate reader. In conclusion, the Au@Pd@Pt NZs-LFIA is a rapid, simple, and sensitive method for detecting the SARS-CoV-2 nucleocapsid protein.